{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:15:22Z","timestamp":1781738122815,"version":"3.54.5"},"reference-count":118,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.jaad.2013.01.043","type":"journal-article","created":{"date-parts":[[2013,4,9]],"date-time":"2013-04-09T17:24:13Z","timestamp":1365528253000},"page":"450-462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["The skin and hypercoagulable states"],"prefix":"10.1016","volume":"69","author":[{"given":"Laura A.","family":"Thornsberry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen I.","family":"LoSicco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Joseph C.","family":"English","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2013.01.043_bib1","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1126\/science.145.3638.1310","article-title":"Waterfall sequence for intrinsic blood clotting","volume":"145","author":"Davie","year":"1964","journal-title":"Science"},{"key":"10.1016\/j.jaad.2013.01.043_bib2","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/202498a0","article-title":"An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier","volume":"202","author":"Macfarlane","year":"1964","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2013.01.043_bib3","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1055\/s-0037-1615947","article-title":"A cell-based model of hemostasis","volume":"85","author":"Hoffman","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jaad.2013.01.043_bib4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0268-960X(03)90000-2","article-title":"A cell-based model of coagulation and the role of factor VIIa","volume":"17","author":"Hoffman","year":"2003","journal-title":"Blood Rev"},{"key":"10.1016\/j.jaad.2013.01.043_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1023\/B:THRO.0000014588.95061.28","article-title":"Remodeling the blood coagulation cascade","volume":"16","author":"Hoffman","year":"2003","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jaad.2013.01.043_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2008-01-077909","article-title":"Advances in understanding pathogenic mechanisms of thrombophilic disorders","volume":"112","author":"Dahlback","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2013.01.043_bib7","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1160\/TH10-10-0683","article-title":"Venous and arterial thrombosis\u2013pathogenesis and the rationale for anticoagulation","volume":"105","author":"Turpie","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jaad.2013.01.043_bib8","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/archinte.166.7.729","article-title":"Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review","volume":"166","author":"Ho","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaad.2013.01.043_bib9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/369064a0","article-title":"Mutation in blood coagulation factor V associated with resistance to activated protein C","volume":"369","author":"Bertina","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2013.01.043_bib10","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1055\/s-0038-1657602","article-title":"The Leiden thrombophilia study (LETS)","volume":"78","author":"van der Meer","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jaad.2013.01.043_bib11","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1097\/PRS.0b013e3181d51344","article-title":"Hereditary coagulopathies: practical diagnosis and management for the plastic surgeon","volume":"125","author":"Friedman","year":"2010","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.jaad.2013.01.043_bib12","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood.V88.10.3698.bloodjournal88103698","article-title":"A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis","volume":"88","author":"Poort","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2013.01.043_bib13","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1046\/j.1365-2141.1999.01149.x","article-title":"The 20210 G\u2192A mutation in the 3'-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease","volume":"104","author":"Franco","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaad.2013.01.043_bib14","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1538-7836.2005.01141.x","article-title":"Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis","volume":"3","author":"den Heijer","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jaad.2013.01.043_bib15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1365-2141.1994.tb04878.x","article-title":"Prevalence of antithrombin deficiency in the healthy population","volume":"87","author":"Tait","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaad.2013.01.043_bib16","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.siny.2011.07.009","article-title":"Diagnosis and management of neonatal purpura fulminans","volume":"16","author":"Price","year":"2011","journal-title":"Semin Fetal Neonatal Med"},{"key":"10.1016\/j.jaad.2013.01.043_bib17","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaad.2013.01.043_bib18","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJM199412153312401","article-title":"A prospective study of venous thromboembolism after major trauma","volume":"331","author":"Geerts","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaad.2013.01.043_bib19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1046\/j.1467-789X.2002.00056.x","article-title":"Obesity, hemostasis and the fibrinolytic system","volume":"3","author":"Mertens","year":"2002","journal-title":"Obes Rev"},{"key":"10.1016\/j.jaad.2013.01.043_bib20","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1161\/01.CIR.97.21.2099","article-title":"American Heart Association call to action: obesity as a major risk factor for coronary artery disease","volume":"97","author":"Eckel","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jaad.2013.01.043_bib21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s004040050193","article-title":"Obesity and hemostasis","volume":"261","author":"Winkler","year":"1997","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.jaad.2013.01.043_bib22","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1001\/jama.287.13.1706","article-title":"Effect of leptin in arterial thrombosis following vascular injury in mice","volume":"287","author":"Bodary","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2013.01.043_bib23","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJMra0801082","article-title":"Mechanisms of thrombus formation","volume":"359","author":"Furie","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2013.01.043_bib24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4048\/jbc.2012.15.2.148","article-title":"Breast cancer as an acquired thrombophilic state","volume":"15","author":"Kyriazi","year":"2012","journal-title":"J Breast Cancer"},{"key":"10.1016\/j.jaad.2013.01.043_bib25","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/s-2005-863812","article-title":"Thrombophilia in cancer","volume":"31","author":"Falanga","year":"2005","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jaad.2013.01.043_bib26","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1161\/ATVBAHA.108.182196","article-title":"New insights into cancer-associated thrombosis","volume":"29","author":"Sousou","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jaad.2013.01.043_bib27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1634\/theoncologist.9-2-207","article-title":"Thrombotic complications of central venous catheters in cancer patients","volume":"9","author":"Kuter","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2013.01.043_bib28","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/annonc\/mdh146","article-title":"Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter","volume":"15","author":"Mandala","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2013.01.043_bib29","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1200\/JCO.2009.22.3271","article-title":"Assessing risk of venous thrombosis in the patient with cancer","volume":"27","author":"Khorana","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2013.01.043_bib30","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1034\/j.1600-0412.1998.770207.x","article-title":"The cumulative incidence of venous thromboembolism during pregnancy and puerperium","volume":"77","author":"Anderson","year":"1998","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.jaad.2013.01.043_bib31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.beha.2012.07.006","article-title":"Venous thromboembolism associated with pregnancy and hormonal therapy","volume":"25","author":"Jacobsen","year":"2012","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jaad.2013.01.043_bib32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bpobgyn.2011.10.003","article-title":"Thromboembolic disorders in obstetrics","volume":"26","author":"Gray","year":"2012","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.jaad.2013.01.043_bib33","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1160\/TH07-05-0359","article-title":"Calibrated automated thrombin generation in normal uncomplicated pregnancy","volume":"99","author":"Rosenkranz","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jaad.2013.01.043_bib34","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1525-1470.1998.1998015169.x","article-title":"Acute infectious purpura fulminans: pathogenesis and medical management","volume":"15","author":"Darmstadt","year":"1998","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib35","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1136\/adc.2010.199919","article-title":"Purpura fulminans: recognition, diagnosis and management","volume":"96","author":"Chalmers","year":"2011","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jaad.2013.01.043_bib36","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/asheducation.V2012.1.610.3798654","article-title":"Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura","volume":"2012","author":"Kremer Hovinga","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jaad.2013.01.043_bib37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2008-02-078170","article-title":"Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura","volume":"112","author":"Sadler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2013.01.043_bib38","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jaad.2008.12.039","article-title":"Warfarin-induced skin necrosis","volume":"61","author":"Nazarian","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1055\/s-0038-1656329","article-title":"Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia","volume":"68","author":"Amiral","year":"1992","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jaad.2013.01.043_bib40","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1055\/s-0032-1306432","article-title":"Heparin-induced thrombocytopenia: an update","volume":"38","author":"Prechel","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jaad.2013.01.043_bib41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.thromres.2007.11.007","article-title":"Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight-heparin, and fondaparinux in different clinical settings","volume":"122","author":"Greinacher","year":"2008","journal-title":"Thromb Res"},{"key":"10.1016\/j.jaad.2013.01.043_bib42","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1111\/j.1538-7836.2005.01632.x","article-title":"Development of antibodies specific to polyanion-modified platelet factor 4 during treatment with fondaparinux","volume":"3","author":"Pouplard","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jaad.2013.01.043_bib43","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1046\/j.1523-1755.2002.00375.x","article-title":"Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy","volume":"61","author":"Fine","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.jaad.2013.01.043_bib44","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2009.12.007","article-title":"Possible role of hypercoagulability in calciphylaxis: review of the literature","volume":"64","author":"Harris","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib45","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1346-8138.2011.01356.x","article-title":"Case of proximal calciphylaxis with protein S deficiency treated with multimodality therapy","volume":"39","author":"Kuba","year":"2012","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib46","first-page":"518","article-title":"Calciphylaxis induced by acquired protein S deficiency in a patient with multiple myeloma\u2013effective treatment with low-molecular-weight heparin","volume":"10","author":"Kerk","year":"2012","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaad.2013.01.043_bib47","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/oxfordjournals.ndt.a027686","article-title":"Calciphylaxis in a hemodialysis patient: functional protein S deficiency?","volume":"11","author":"Perez-Mijares","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jaad.2013.01.043_bib48","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1159\/000168900","article-title":"Calciphylaxis in a chronic hemodialysis patient with protein S deficiency","volume":"15","author":"Rostaing","year":"1995","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jaad.2013.01.043_bib49","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1067\/mjd.2000.103276","article-title":"Calciphylaxis and antiphospholipid antibody syndrome","volume":"42","author":"Wong","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib50","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2215\/CJN.00530108","article-title":"Calciphylaxis from nonuremic causes: a systematic review","volume":"3","author":"Nigwekar","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2013.01.043_bib51","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/j.jaad.2003.11.050","article-title":"Calciphylaxis associated with acute, reversible renal failure in setting of alcoholic cirrhosis","volume":"50","author":"Chavel","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib52","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/01.SMJ.0000154316.22472.97","article-title":"Calciphylaxis: a rare association with alcoholic cirrhosis. Are deficiencies in protein C and S the cause?","volume":"98","author":"Goli","year":"2005","journal-title":"South Med J"},{"key":"10.1016\/j.jaad.2013.01.043_bib53","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1046\/j.1365-2133.2000.03853.x","article-title":"Calciphylaxis in a patient without renal failure or elevated parathyroid hormone: possible etiological role of chemotherapy","volume":"143","author":"Goyal","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib54","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s100670200016","article-title":"Calciphylaxis in a patient with rheumatoid arthritis without renal failure and hyperparathyroidism: the possible role of long-term steroid use and protein S deficiency","volume":"21","author":"Korkmaz","year":"2002","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib55","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1053\/ajkd.1998.v32.pm9740153","article-title":"Cutaneous necrosis from calcific uremic arteriolopathy","volume":"32","author":"Coates","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jaad.2013.01.043_bib56","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1001\/archderm.140.9.1045","article-title":"Low-dose tissue plasminogen activator for calciphylaxis","volume":"140","author":"Sewell","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib57","first-page":"330","article-title":"Pathogenesis of antiphospholipid syndrome: understanding the antibodies","volume":"7","author":"Meroni","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2013.01.043_bib58","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jaad.2013.01.043_bib59","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1055\/s-0032-1304718","article-title":"Update on the catastrophic antiphospholipid syndrome and the CAPS registry","volume":"38","author":"Cervera","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jaad.2013.01.043_bib60","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s12016-007-0011-1","article-title":"Primary anetoderma and antiphospholipid antibodies\u2013review of the literature","volume":"32","author":"Hodak","year":"2007","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaad.2013.01.043_bib61","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1002\/art.21063","article-title":"Clinical images: anetoderma in systemic lupus erythematosus with antiphospholipid antibodies","volume":"52","author":"Venhoff","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2013.01.043_bib62","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1191\/0961203303lu431cr","article-title":"Anetoderma associated with antiphospholipid syndrome and systemic lupus erythematosus","volume":"12","author":"Bilen","year":"2003","journal-title":"Lupus"},{"key":"10.1016\/j.jaad.2013.01.043_bib63","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1191\/0961203303lu1058xx","article-title":"Anetoderma associated with systemic lupus erythematosus and antiphospholipid antibodies","volume":"13","author":"Sabio","year":"2004","journal-title":"Lupus"},{"key":"10.1016\/j.jaad.2013.01.043_bib64","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0190-9622(08)81902-0","article-title":"Primary anetoderma associated with the antiphospholipid syndrome","volume":"30","author":"Disdier","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib65","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0190-9622(03)02110-8","article-title":"Anetoderma and its prothrombotic abnormalities","volume":"49","author":"Sparsa","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib66","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jaad.2006.10.046","article-title":"Anetoderma associated with primary antiphospholipid syndrome","volume":"56","author":"de Souza","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib67","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1468-3083.2001.00255.x","article-title":"Anetoderma associated with the antiphospholipid antibodies: case report and review of the literature","volume":"15","author":"Romani","year":"2001","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2013.01.043_bib68","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/096120330000900712","article-title":"Anetoderma in systemic lupus erythematosus: relationship to antiphospholipid antibodies","volume":"9","author":"Montilla","year":"2000","journal-title":"Lupus"},{"key":"10.1016\/j.jaad.2013.01.043_bib69","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1365-2230.2003.01139.x","article-title":"Systemic lupus erythematosus-associated anetoderma and anti-phospholipid antibodies","volume":"28","author":"Fernandez-Galar","year":"2003","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib70","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1191\/0961203303lu403oa","article-title":"Primary anetoderma: a cutaneous sign of antiphospholipid antibodies","volume":"12","author":"Hodak","year":"2003","journal-title":"Lupus"},{"key":"10.1016\/j.jaad.2013.01.043_bib71","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jaad.2010.09.720","article-title":"Thrombosis-induced ulcerations of the lower legs with coexistent anetoderma due to anti-thrombin III deficiency","volume":"65","author":"Clark","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib72","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jaad.2004.11.051","article-title":"Livedo reticularis: an update","volume":"52","author":"Gibbs","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib73","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/archderm.1987.01660290064017","article-title":"Livedo reticularis associated with increased titers of anticardiolipin antibodies in systemic lupus erythematosus","volume":"123","author":"Weinstein","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib74","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/archderm.1963.01590150015002","article-title":"Livedo reticularis in systemic lupus erythematosus","volume":"87","author":"Golden","year":"1963","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib75","first-page":"2379","article-title":"Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome","volume":"33","author":"Uthman","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib76","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/art.21041","article-title":"Dermatologic manifestations of the antiphospholipid syndrome","volume":"52","author":"Frances","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2013.01.043_bib77","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/archderm.142.1.75","article-title":"Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia","volume":"142","author":"Browning","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib78","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1001\/archderm.142.11.1413","article-title":"Livedoid vasculopathy: further evidence for procoagulant pathogenesis","volume":"142","author":"Hairston","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib79","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.autrev.2010.11.008","article-title":"Livedoid vasculopathy as a coagulation disorder","volume":"10","author":"Criado","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaad.2013.01.043_bib80","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1034\/j.1600-0560.2000.027008410.x","article-title":"Livedoid vasculopathy in a patient with factor V mutation (Leiden)","volume":"27","author":"Biedermann","year":"2000","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2013.01.043_bib81","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1067\/mjd.2002.117718","article-title":"Livedo (livedoid) vasculitis and the factor V Leiden mutation: additional evidence for abnormal coagulation","volume":"46","author":"Calamia","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib82","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00105-004-0709-4","article-title":"Livedoid vasculopathy with heterozygous factor V Leiden mutation and sticky platelet syndrome","volume":"55","author":"Lewerenz","year":"2004","journal-title":"Hautarzt"},{"key":"10.1016\/j.jaad.2013.01.043_bib83","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/archderm.139.8.1081-b","article-title":"Heterozygous prothrombin G20210A gene mutation in a patient with livedoid vasculitis","volume":"139","author":"Gotlib","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib84","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1440-0960.2007.00350.x","article-title":"Heterozygous prothrombin gene mutation associated with livedoid vasculopathy","volume":"48","author":"Anavekar","year":"2007","journal-title":"Australas J\u00a0Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib85","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/archderm.138.6.841","article-title":"Livedoid vasculitis with ulcerations: the role of antithrombin III deficiency and its therapeutic consequences","volume":"138","author":"Hegemann","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib86","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1046\/j.1365-2133.2000.03786.x","article-title":"Livedoid vasculopathy associated with heterozygous protein C deficiency","volume":"143","author":"Boyvat","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib87","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/archderm.1992.01680200122031","article-title":"Livedo vasculitis with protein C system deficiency","volume":"128","author":"Baccard","year":"1992","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib88","doi-asserted-by":"crossref","first-page":"e811","DOI":"10.1111\/j.1365-2230.2009.03541.x","article-title":"Livedoid vasculitis associated with double heterozygous factor V Leiden and prothrombin G20210A gene mutations","volume":"34","author":"Khenifer","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib89","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1046\/j.1365-2133.1998.02541.x","article-title":"Livedoid vasculitis with anticardiolipin antibodies: improvement with danazol","volume":"139","author":"Wakelin","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib90","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0190-9622(89)70133-X","article-title":"Thrombotic skin disease as a marker of the anticardiolipin syndrome: livedo vasculitis and distal gangrene associated with abnormal serum antiphospholipid activity","volume":"20","author":"Grob","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib91","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2133.1999.02622.x","article-title":"Livedoid vasculitis: a manifestation of the antiphospholipid syndrome?","volume":"140","author":"Acland","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib92","first-page":"159","article-title":"Livedoid vasculopathy: the role of hyperhomocysteinemia and its simple therapeutic consequences","volume":"16","author":"Meiss","year":"2006","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib93","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0190-9622(99)70207-0","article-title":"Homocysteinemia and livedoid vasculitis","volume":"40","author":"Gibson","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib94","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1365-2133.2006.07448.x","article-title":"Methylenetetrahydrofolate reductase polymorphism associated with moderate hyperhomocysteinemia in a patient with livedo vasculopathy: treatment with vitamin supplementation and low weight molecular heparin","volume":"155","author":"Rampf","year":"2006","journal-title":"Br J\u00a0Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib95","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1524-475X.2011.00716.x","article-title":"Prevalence rate for inherited thrombophilia in patients with chronic and recurrent venous leg ulceration","volume":"19","author":"Wiszniewski","year":"2011","journal-title":"Wound Repair Regen"},{"key":"10.1016\/j.jaad.2013.01.043_bib96","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1067\/mva.2002.121749","article-title":"The prevalence of thrombophilia in patients with chronic venous leg ulceration","volume":"35","author":"Mackenzie","year":"2002","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jaad.2013.01.043_bib97","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archdermatol.2009.123","article-title":"Association between superficial vein thrombosis and deep vein thrombosis of the lower extremities","volume":"145","author":"Binder","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib98","doi-asserted-by":"crossref","first-page":"218","DOI":"10.7326\/0003-4819-152-4-201002160-00006","article-title":"POST (Prospective Observational Superficial Thrombophlebitis) Study Group. Superficial vein thrombosis and venous thromboembolism: a large prospective epidemiologic study","volume":"152","author":"Decousus","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2013.01.043_bib99","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1160\/TH10-06-0406","article-title":"Predictive factors for concurrent deep-vein thrombosis and symptomatic venous thromboembolic recurrence in case of superficial venous thrombosis: the OPTIMEV study","volume":"105","author":"Galanaud","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jaad.2013.01.043_bib100","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.disamonth.2010.06.006","article-title":"Anticoagulant treatment for superficial venous thrombosis","volume":"56","author":"Carnero-Vidal","year":"2010","journal-title":"Dis Mon"},{"key":"10.1016\/j.jaad.2013.01.043_bib101","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.beha.2012.07.005","article-title":"Epidemiology, diagnosis, treatment and management of superficial-vein thrombosis of legs","volume":"25","author":"Decousus","year":"2012","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jaad.2013.01.043_bib102","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/153100350501700108","article-title":"Superficial vein thrombosis and hypercoagulable states: the evidence","volume":"17","author":"Leon","year":"2005","journal-title":"Perspect Vasc Surg Endovasc Ther"},{"key":"10.1016\/j.jaad.2013.01.043_bib103","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/000331970105200206","article-title":"Superficial vein thrombosis and anticardiolipin antibodies\u2013report of association","volume":"52","author":"de Godoy","year":"2001","journal-title":"Angiology"},{"key":"10.1016\/j.jaad.2013.01.043_bib104","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/107602960300900108","article-title":"Protein S deficiency in repetitive superficial thrombosis","volume":"9","author":"de Godoy","year":"2003","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jaad.2013.01.043_bib105","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0741-5214(98)70233-2","article-title":"Saphenous vein thrombosis (SVT): a deceptively benign disease","volume":"27","author":"Hanson","year":"1998","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jaad.2013.01.043_bib106","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1055\/s-0037-1615180","article-title":"Superficial vein thrombosis of the lower limb: influence of factor V Leiden, factor G20210A and overweight","volume":"80","author":"de Moerloose","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jaad.2013.01.043_bib107","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1055\/s-0037-1614362","article-title":"Genetic risk factors for superficial vein thrombosis","volume":"82","author":"Martinelli","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jaad.2013.01.043_bib108","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1001\/archderm.139.8.987","article-title":"Treatment of livedoid vasculopathy with low-molecular-weight-heparin: report of two cases","volume":"139","author":"Hairston","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib109","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/j.1468-3083.2010.03646.x","article-title":"Frequency of thrombophilia determinant factors in patients with livedoid vasculopathy and treatment with anti-coagulant drugs\u2013a prospective study","volume":"24","author":"Di Giacomo","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2013.01.043_bib110","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/bjd.12100","article-title":"Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathy","volume":"168","author":"Kerk","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib111","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s11239-012-0743-5","article-title":"Livedoid vasculopathy in a patient with lupus anticoagulant and MTHFR mutation: treatment with low-molecular-weight heparin","volume":"34","author":"Abou Rahal","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jaad.2013.01.043_bib112","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/09546630701670305","article-title":"A case of livedoid vasculopathy associated with factor V Leiden mutation: successful treatment with oral warfarin","volume":"19","author":"Kavala","year":"2008","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2013.01.043_bib113","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaad.2006.04.087","article-title":"Ulcerations caused by livedoid vasculopathy associated with a prothrombotic state: response to warfarin","volume":"58","author":"Davis","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.01.043_bib114","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMra002974","article-title":"The antiphospholipid syndrome","volume":"346","author":"Levine","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2013.01.043_bib115","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1056\/NEJMoa0912072","article-title":"Fondaparinux in the treatment of superficial-vein thrombosis in the legs","volume":"363","author":"Decousus","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2013.01.043_bib116","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/j.1538-7836.2012.04727.x","article-title":"A randomized double-blind study of low-molecular weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (superficial thromboembolism and Fluxum)","volume":"10","author":"Cosmi","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jaad.2013.01.043_bib117","first-page":"CD004982","article-title":"Treatment for superficial thrombophlebitis of the leg","volume":"3","author":"Di Nisio","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2013.01.043_bib118","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962213002119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962213002119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:27:23Z","timestamp":1759271243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962213002119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":118,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0190962213002119"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2013.01.043","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The skin and hypercoagulable states","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2013.01.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}